Oncologic treatment strategies and relative survival of patients with stage I-III rectal cancer - A EURECCA international comparison between the Netherlands, Belgium, Denmark, Sweden, England, Ireland, Spain, and Lithuania

A. J. Breugom, E. Bastiaannet, P. G. Boelens, E. Van Eycken, L. H. Iversen, A. Martling, R. Johansson, T. Evans, S. Lawton, K. M. O'Brien, H. Ortiz, R. Janciauskiene, O. M. Dekkers, H. J. T. Rutten, G. J. Liefers, V. E. P. P. Lemmens, C. J. H. van de Velde*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Web of Science)
12 Downloads (Pure)

Abstract

Introduction: The aim of this EURECCA international comparison is to compare oncologic treatment strategies and relative survival of patients with stage I-III rectal cancer between European countries.

Material and methods: Population-based national cohort data from the Netherlands (NL), Belgium (BE), Denmark (DK), Sweden (SE), England (ENG), Ireland (IE), Spain (ES), and single-centre data from Lithuania (LT) were obtained. All operated patients with (y)pTNM stage I-III rectal cancer diagnosed between 2004 and 2009 were included. Oncologic treatment strategies and relative survival were calculated and compared between neighbouring countries.

Results: We included 57,120 patients. Treatment strategies differed between NL and BE (p <0.001), DK and SE (p <0.001), and ENG and IE (p <0.001). More preoperative radiotherapy as single treatment before surgery was administered in NL compared with BE (59.7% vs. 13.1%), in SE compared with DK (55.1% vs. 10.4%), and in ENG compared with IE (15.2% vs. 9.6%). Less postoperative chemotherapy was given in NL (9.6% vs. 39.1%), in SE (7.9% vs. 14.1%), and in IE (12.6% vs. 18.5%) compared with their neighbouring country. In ES, 55.1% of patients received preoperative chemoradiation and 62.3% post-operative chemotherapy. There were no significant differences in relative survival between neighbouring countries.

Conclusion: Large differences in oncologic treatment strategies for patients with (y)pTNM I-III rectal cancer were observed across European countries. No clear relation between oncologic treatment strategies and relative survival was observed. Further research into selection criteria for specific treatments could eventually lead to individualised and optimal treatment for patients with non-metastasised rectal cancer. (C) 2018 Published by Elsevier Ltd.

Original languageEnglish
Pages (from-to)1338-1343
Number of pages6
JournalEuropean Journal of Surgical Oncology
Volume44
Issue number9
DOIs
Publication statusPublished - Sep 2018

Keywords

  • Rectal cancer
  • International comparison
  • Population-based
  • Stage I-III
  • Surgery
  • Oncologic treatment
  • TOTAL MESORECTAL EXCISION
  • PREOPERATIVE RADIOTHERAPY
  • ADJUVANT CHEMOTHERAPY
  • POSTOPERATIVE CHEMOTHERAPY
  • OPEN-LABEL
  • FOLLOW-UP
  • OXALIPLATIN
  • TRIAL
  • CHEMORADIOTHERAPY
  • FLUOROURACIL

Cite this